Transpl Int . Anti-HLA and anti-SARS-CoV2 Antibodies in Kidney Transplant Recipient with COVID-19

[tetano]

Transpl Int


. 2021 Jan 22.
doi: 10.1111/tri.13829. Online ahead of print.
Anti-HLA and anti-SARS-CoV2 Antibodies in Kidney Transplant Recipient with COVID-19


Ilaria Gandolfini[SUP] 1 [/SUP], Paola Zanelli[SUP] 2 [/SUP], Alessandra Palmisano[SUP] 1 [/SUP], Daniel Salvetti[SUP] 1 [/SUP], Alice Parmigiani[SUP] 1 [/SUP], Jonathan S Maltzman[SUP] 3 [/SUP], Claudia Labate[SUP] 2 [/SUP], Enrico Fiaccadori[SUP] 1 [/SUP], Paolo Cravedi[SUP] 4 [/SUP], Umberto Maggiore[SUP] 1 [/SUP]



Affiliations

• PMID: 33481306
• DOI: 10.1111/tri.13829

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated illness coronavirus disease 2019 (COVID-19) have severely affected organ transplant recipients, with all-cause mortality rates exceeding 20% (1, 2). Although no clear guidelines exist on how to adjust immunosuppression, most centers reduce anti-rejection drugs to facilitate the T and B cell response against the virus.

Keywords: COVID-19; alloantibodies; donor-specific antibodies; kidney transplantation.